HAART is associated with lower hepatic necroinflammatory activity in HIV-hepatitis C virus- coinfected patients with CD4 cell count of more than 350 cells/μl at the time of liver biopsy

AIDS

Volumn 23, Issue 8, 2009, Pages 971-975

  Pascual Pareja, José F ^a,b   Caminoa, Alejandra ^a   Larrauri, Javier ^a   González García, Juan ^a   Montes, Maria L ^a   Díez, Jesús ^a   Grande, Marta ^a   Arribas, José R ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Haart; Hepatic necroinflammation; Hepatitis C; HIV; Liver fibrosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; HEPATITIS B SURFACE ANTIBODY;

ADULT; ALCOHOL ABUSE; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER BIOPSY; LIVER INJURY; LIVER NECROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCORING SYSTEM;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; FEMALE; FIBROSIS; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER; MALE; SPAIN;

EID: 67049160288     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328329f994     Document Type: Article

References (19)

1. Lewden C, May T, Rosenthal E, Burty C, Bonnet F, Costagliola D, et al., ANRS EN19 Mortalité Study Group and Mortavicl. Changes in causes of death among adults infected by HIV between 2000 and 2005: the 'Mortalité 2000 and 2005' surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008; 48:590-598.
2. Rodríguez-Torres M, Rodríguez-Orengo JF, Ríos-Bedoya CF, Fernández-Carbia A, Marxuach-Cuétara AM, López-Torres A, et al. Effect of hepatitis C virus treatment in fibrosis progression rate (FPR) and time to cirrhosis (TTC) in patients co-infected with human immunodeficiency virus: A paired liver biopsy study. J Hepatol 2007; 46:613-619.
3. Berenguer J, Alvarez-Pel Iicer J, Lopez Aldeguer J, Von-Wichman M, Quereda C, Mallolas J, et al.; and the GESIDA 3603 Study Group. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in HIV/HCV-co-infected patients [oral abstract #60]. 15th Conference on Retroviruses and Opportunistic Infections; 3-6 February 2008; Boston, Massachusetts; 2008.
4. Fleming C, Craven D, Thorton D, Tumilty S, Nunes D. Hepatitis C virus and HIV co-infection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 2003; 36:97-100.
5. Rauch A, EggerM, ReichenJ, FurrerH, Swiss HIV Cohort Study. Chronic hepatitis C in HIV-infected patients: low eligibility and applicability of therapy with pegylated interferon-alpna plus ribavirin. J Acquir Immune Defic Syndr 2005; 38:238-240.
6. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351:451-459.
7. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gon-zalez-García J, Lazzarin A, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV infected patients. N Engl J Med 2004; 351:438-450.
8. Puoti M, Bonacini M, Spinetti A, Putzolu V, Covindarajan S, Zaltron S, et al., HIV-HCV Coinfection Study Group. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J Infect Dis 2001; 183:134-137.
9. Verma S, Wang CH, Govindarajan S, Kanel G, Squires K, Bonacini M. Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C virus-coinfected patients? Clin Infect Dis 2006; 42:262-270.
10. Marine-Barjoan E, Saint-Paul MC, Pradier C, Chaillou S, Anty R, Michiels JF, et al. Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C virus co-infected patients. AIDS 2004; 18:2163-2170.
11. Panel on antiretroviral guidelines for adult and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services; 2008. pp. 1-128. http://www.aidsinfo.nih.gov/Con-tentFiles/AdultandAdolescentGL.pdf.
12. Clumeck N, Pozniak A, Raffi F, EACS Executive Committee. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med 2008; 9:65-71.
13. Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, et al., International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-570.
14. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13:372-374.
15. Tuyama AC, Hong F, Schecter AD. HIV entry and replication in stellate cells promotes cellular activation and fibrogenesis: implications for hepatic fibrosis in HIV/HCV co-infection [abstract #LB3]. 58th Annual Meeting of the American Association for the Study of Liver Diseases; 2-6 November 2007; Boston, Massachusetts; 2007.
16. Bruno R, Galastri S, Marra F. Gp120 induces directional migration of human hepatic stellate cells: a link between HIV infection and liver fibrogenesis [abstract #125]. 58th Annual Meeting of the American Association for the Study of Liver Diseases; 2-6 November 2007; Boston, Massachusetts; 2007.
17. Bräu N, Salvatore M, Rios-Bedoya CF, Fernández-Carbia A, Paronetto F, Rodríguez-OrengoJF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44: 47-55.
18. Lin W, Weinberg EM, Tai AW, Peng LF, Brockman MA, Kim KA, et al. HIV increases HCV replication in a TGF-betal -dependent manner. Gastroenterology 2008; 134:803-811.
19. Kuntzen T, Tural C, Li B, Feldmann G, Kupfer B, Nischalke HD, et al. Intrahepatic mRNA expression in hepatitis C virus and HIV/hepatitis C virus co-infection: infiltrating cells, cytokines, and influence of HAART. AIDS 2008; 22:203-210.